About Hydroxycarboxylic acid receptor 2
Hydroxycarboxylic acid receptor 2 (HCAR2) is a protein
from Homo sapiens identified by UniProt accession
Q8TDS4, 363 residues long.
MolForge cross-references it against 0 known binders and
167 disease associations.
Target properties
| Protein name | Hydroxycarboxylic acid receptor 2 |
| UniProt accession | Q8TDS4 |
| Gene | HCAR2 |
| Organism | Homo sapiens |
| Length | 363 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (7)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (167)
Diseases linked to this target (Open Targets).
- Red cell distribution width · score 0.29
- high density lipoprotein cholesterol measurement · score 0.28
- mean corpuscular volume · score 0.26
- triglyceride measurement · score 0.26
- waist-hip ratio · score 0.26
- glioblastoma multiforme · score 0.25
- Oral ulcer · score 0.21
- BMI-adjusted waist-hip ratio · score 0.21
- BMI-adjusted waist circumference · score 0.21
- platelet-to-lymphocyte ratio · score 0.21
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8TDS4-F1 | alphafold | PREDICTED | 82.73 | — |
Amino-acid sequence (363 residues)
MNRHHLQDHF LEIDKKNCCV FRDDFIVKVL PPVLGLEFIF GLLGNGLALW IFCFHLKSWK SSRIFLFNLA VADFLLIICL PFLMDNYVRR WDWKFGDIPC RLMLFMLAMN RQGSIIFLTV VAVDRYFRVV HPHHALNKIS NRTAAIISCL LWGITIGLTV HLLKKKMPIQ NGGANLCSSF SICHTFQWHE AMFLLEFFLP LGIILFCSAR IIWSLRQRQM DRHAKIKRAI TFIMVVAIVF VICFLPSVVV RIRIFWLLHT SGTQNCEVYR SVDLAFFITL SFTYMNSMLD PVVYYFSSPS FPNFFSTLIN RCLQRKMTGE PDNNRSTSVE LTGDPNKTRG APEALMANSG EPWSPSYLGP TSP
Explore Hydroxycarboxylic acid receptor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets